<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016068</url>
  </required_header>
  <id_info>
    <org_study_id>1577.00</org_study_id>
    <secondary_id>FHCRC-1577.00</secondary_id>
    <secondary_id>MSKCC-01127</secondary_id>
    <secondary_id>NCI-H01-0072</secondary_id>
    <nct_id>NCT00016068</nct_id>
  </id_info>
  <brief_title>Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation</brief_title>
  <official_title>A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in&#xD;
      preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing&#xD;
      cytomegalovirus.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works&#xD;
      in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare cytomegalovirus (CMV) disease and non-CMV invasive infection-free survival in&#xD;
           patients undergoing allogeneic hematopoietic stem cell transplantation treated with&#xD;
           valganciclovir vs placebo.&#xD;
&#xD;
        -  Compare the incidence of CMV disease in patients treated with these drugs.&#xD;
&#xD;
        -  Compare the incidence of other severe invasive bacterial and fungal infections and&#xD;
           overall survival in patients treated with these drugs.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the incidence of CMV infection or disease at baseline and at days 270 and 640&#xD;
           after allogeneic hematopoietic stem cell transplantation in patients treated with these&#xD;
           drugs.&#xD;
&#xD;
        -  Compare the incidence of herpes simplex virus and varicella-zoster virus infections at&#xD;
           baseline and day 270 in patients treated with these drugs.&#xD;
&#xD;
        -  Determine the safety of valganciclovir in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these drugs.&#xD;
&#xD;
        -  Compare CMV-specific immune reconstitution in patients treated with these drugs.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to participating center, prior neutropenia (yes vs no), and presence&#xD;
      of refractory graft-versus-host disease requiring secondary therapy (yes vs no). Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral valganciclovir daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo daily. Treatment begins around day 80-120&#xD;
           post-transplantation and continues until day 270 post-transplantation in the absence of&#xD;
           active infection or unacceptable toxicity. Patients developing active cytomegalovirus&#xD;
           (CMV) infection receive induction doses of ganciclovir IV or open-label oral&#xD;
           valganciclovir for 1 week followed by open-label oral valganciclovir maintenance dosing&#xD;
           until CMV can no longer be detected.&#xD;
&#xD;
      Quality of life is assessed at baseline and days 180 and 270 post-transplantation.&#xD;
&#xD;
      Patients are followed at days 400, 520, and 640 post-transplantation.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 184 patients (92 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late cytomegalovirus infection by plasma PCR positivity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganciclovir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Have undergone allogeneic peripheral blood stem cell, cord blood, or marrow&#xD;
             transplantation (related or unrelated, T-cell depleted or non-T-cell depleted,&#xD;
             CD34-selected or non-selected, or myeloablative or non-myeloablative) within the past&#xD;
             80-120 days&#xD;
&#xD;
          -  Positive pre-transplantation cytomegalovirus (CMV) serology of recipient and/or donor&#xD;
&#xD;
               -  Seropositive recipients with one of the following:&#xD;
&#xD;
                    -  CMV infection before day 80, as determined by:&#xD;
&#xD;
                         -  pp65 antigenemia&#xD;
&#xD;
                         -  CMV DNA in plasma&#xD;
&#xD;
                         -  Peripheral blood leukocytes (PBL) or whole blood at any level detected&#xD;
                            by polymerase chain reaction or hybrid capture&#xD;
&#xD;
                         -  CMV pp67 mRNA&#xD;
&#xD;
                         -  CMV viremia by blood culture&#xD;
&#xD;
                         -  Surveillance bronchoalveolar lavage (culture or cytology)&#xD;
&#xD;
                    -  CMV disease more than 6 weeks prior to enrollment&#xD;
&#xD;
                    -  Presence of graft-versus-host disease (GVHD) at enrollment&#xD;
&#xD;
                         -  Acute GVHD that requires treatment with systemic corticosteroids of&#xD;
                            doses greater than 0.5 mg/kg OR&#xD;
&#xD;
                         -  Chronic clinically extensive GVHD requiring treatment with&#xD;
                            corticosteroids&#xD;
&#xD;
                    -  Continuous prophylaxis with ganciclovir, foscarnet, or cidofovir between&#xD;
                       engraftment and day 80 OR&#xD;
&#xD;
               -  Seronegative recipient with seropositive donor who has CMV infection before day&#xD;
                  80&#xD;
&#xD;
          -  No rising or uncontrolled CMV load (pp65 antigenemia levels no greater than 1/slide or&#xD;
             no greater than 100 copies of CMV DNA per mL of plasma or per million PBL allowed)&#xD;
&#xD;
          -  No CMV disease within 6 weeks prior to randomization&#xD;
&#xD;
          -  No leukemic relapse&#xD;
&#xD;
               -  Cytogenetic or molecular relapse allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 2 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3 for at least 1 week prior to enrollment&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.5 mg/mL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No hypersensitivity to ganciclovir or valganciclovir&#xD;
&#xD;
          -  No uncontrolled diarrhea or severe gastrointestinal disease that would preclude oral&#xD;
             medication&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 90 days after study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Proficient in English&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Prior ganciclovir, foscarnet, cidofovir, high-dose acyclovir, or valacyclovir as&#xD;
             prophylaxis or preemptive therapy allowed&#xD;
&#xD;
          -  No concurrent prophylactic foscarnet, cidofovir, or ganciclovir (IV or oral)&#xD;
&#xD;
          -  No concurrent prophylactic high-dose acyclovir (more than 800 mg twice daily),&#xD;
             valacyclovir (more than 500 mg twice daily), cidofovir (more than 0.5 mg/kg per week),&#xD;
             or famciclovir (more than 500 mg/day) except for limited treatment courses at higher&#xD;
             doses for varicella-zoster virus infections&#xD;
&#xD;
               -  Concurrent low-dose (â‰¤ 0.5 mg/kg per week) cidofovir allowed for limited&#xD;
                  treatment courses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boeckh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 14, 2010</last_update_submitted>
  <last_update_submitted_qc>May 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2010</last_update_posted>
  <keyword>infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

